Table 2.
Overall completion rates for each HRQL measure at end of core phase (week 18) across treatment arms.
| HRQL measure | Total % (n/N) | LE (n/N) | HE (n/N) | Placebo (n/N) |
|---|---|---|---|---|
| QOLCE | 84% (N = 166/197) | 54/65 | 58/69 | 54/63 |
| QOLIE-AD-48 | 36% (N = 37/102) | 13/31 | 14/38 | 10/33 |
| QOLIE-31-P | 49% (N = 33/67) | 10/21 | 11/23 | 12/23 |
HE, high exposure; LE, low exposure.